Barinthus Bio Announces Topline Data From Phase 1B/2 APOLLO Trial Of VTP-200 In Persistent High-Risk Human Papillomavirus (HPV) Infections menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Barinthus HPV-related cancer drug doesn't prove efficacy fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted, though not statistically significant. No major safety concerns were observed.
Primary safety endpoint met; VTP-200 was generally well-tolerated, with no treatment-related grade 3 or higher adverse events or serious AEs . Positive trends in clearance rate for both high-risk HPV.